Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Letrozole in HR+ Advanced Breast Cancer
NCT00073528Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2003
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Lapatinib + Letrozole with Placebo + Letrozole (2 arms). Primary endpoint: Progression Free Survival in HER2-Positive Population up to 46 months. Started Dec 2003; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00073528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073528.